Portal de Periódicos da CAPES

Enantioselective Access to Chiral Drugs by using Asymmetric Hydrogenation Catalyzed by Rh(POP) Complexes

2011; Wiley; Volume: 17; Issue: 50 Linguagem: Inglês

10.1002/chem.201103014

1521-3765

Pablo Etayo, José Luis Núñez‐Rico, Héctor Fernández, Anton Vidal‐Ferran,

Catalysis for Biomass Conversion

Chemistry – A European JournalVolume 17, Issue 50 p. 13978-13982 Communication Enantioselective Access to Chiral Drugs by using Asymmetric Hydrogenation Catalyzed by Rh(POP) Complexes Dr. Pablo Etayo, Dr. Pablo Etayo Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this authorJosé Luis Núñez-Rico, José Luis Núñez-Rico Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this authorDr. Héctor Fernández-Pérez, Dr. Héctor Fernández-Pérez Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this authorProf. Anton Vidal-Ferran, Corresponding Author Prof. Anton Vidal-Ferran [email protected] Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228 Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, 08010 Barcelona (Spain)Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this author Dr. Pablo Etayo, Dr. Pablo Etayo Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this authorJosé Luis Núñez-Rico, José Luis Núñez-Rico Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this authorDr. Héctor Fernández-Pérez, Dr. Héctor Fernández-Pérez Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this authorProf. Anton Vidal-Ferran, Corresponding Author Prof. Anton Vidal-Ferran [email protected] Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228 Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, 08010 Barcelona (Spain)Institute of Chemical Research of Catalonia (ICIQ), Avgda. Països Catalans 16, 43007 Tarragona (Spain), Fax: (+34) 977920-228Search for more papers by this author First published: 22 November 2011 https://doi.org/10.1002/chem.201103014Citations: 32Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Graphical Abstract POP art: Rhodium complexes of POP ligands serve as highly efficient and enantioselective catalysts in asymmetric hydrogenation leading to various valuable pharmaceutical building blocks and several direct precursors of chiral drugs such as LY2497282, lacosamide, rivastigmine, and aprepitant and 12 further examples (see scheme; nbd=norbornadiene; XC(O)G=NHAc, NHBoc, NHCbz, 2-oxopyrrolidin-1-yl, OAc). Supporting Information Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Filename Description chem_201103014_sm_miscellaneous_information.pdf595 KB miscellaneous_information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. References 1See, for example: 1aV. Farina, J. T. Reeves, C. H. Senanayake, J. J. Song, Chem. Rev. 2006, 106, 2734; 1b Asymmetric Catalysis on Industrial Scale: Challenges, Approaches, and Solutions, 2nd ed. ), Wiley-VCH, Weinheim, 2010. 2See, for example: 2aS. J. Roseblade, A. Pfaltz, Acc. Chem. Res. 2007, 40, 1402; 2b Phosphorus Ligands in Asymmetric Catalysis Vol. I–III, 1st ed. ), Wiley-VCH, Weinheim, 2008; 2cJ.-H. Xie, S.-F. Zhu, Q.-L. Zhou, Chem. Rev. 2011, 111, 1713. 3See, for example: 3aT. C. Nugent, M. El-Shazly, Adv. Synth. Catal. 2010, 352, 753; 3bC. A. Busacca, D. R. Fandrick, J. J. Song, C. H. Senanayake, Adv. Synth. Catal. 2011, 353, 1825. 4For a comprehensive review describing the synthesis of this kind of phosphorus ligands and their applications in asymmetric catalysis, see: H. Fernández-Pérez, P. Etayo, A. Panossian, A. Vidal-Ferran, Chem. Rev. 2011, 111, 2119. 5A. Panossian, H. Fernández-Pérez, D. Popa, A. Vidal-Ferran, Tetrahedron: Asymmetry 2010, 21, 2281. 6J. L. Núñez-Rico, H. Fernández-Pérez, J. Benet-Buchholz, A. Vidal-Ferran, Organometallics 2010, 29, 6627. 7 7aH. Fernández-Pérez, M. A. Pericàs, A. Vidal-Ferran, Adv. Synth. Catal. 2008, 350, 1984; 7bS. M. A. Donald, A. Vidal-Ferran, F. Maseras, Can. J. Chem. 2009, 87, 1273; 7cH. Fernández-Pérez, S. M. A. Donald, I. J. Munslow, J. Benet-Buchholz, F. Maseras, A. Vidal-Ferran, Chem. Eur. J. 2010, 16, 6495; 7dH. Fernández-Pérez, P. Etayo, J. L. Núñez-Rico, A. Vidal-Ferran, Chim. Oggi 2010, 28, XXVI. 8See the Supporting Information for details. 9For a closely related precedent on such a side reaction, see S. E. Ramer, R. N. Moore, J. C. Vederas, Can. J. Chem. 1986, 64, 706. 10 10aS.-H. Park, S.-H. Kang, S.-H. Lim, H.-S. Oh, K.-H. Lee, Bioorg. Med. Chem. Lett. 2003, 13, 3455; 10bS.-H. Park, H.-S. Oh, M.-A. Kang, H. Cho, J. B. Prasad, J. Won, K.-H. Lee, Bioorg. Med. Chem. 2007, 15, 3938, and references therein. 11See W. S. Knowles, Angew. Chem. 2002, 114, 2096; Angew. Chem. Int. Ed. 2002, 41, 1998, and references therein. 12H. Yu, R. N. Richey, J. R. Stout, M. A. LaPack, R. Gu, V. V. Khau, S. A. Frank, J. P. Ott, R. D. Miller, M. A. Carr, T. Y. Zhang, Org. Process Res. Dev. 2008, 12, 218. 13L. C. Blaszczak, B. M. Mathes, S. R. Pulley, M. A. Robertson, S. M. Sheehan, Q. Shi, B. M. Watson, M. R. Wiley (Eli Lilly and Company), WO 015 767, 2007. 14 14aB. Allison, V. K. Phuong, M. C. W. Pippel, M. H. Rabinowitz, H. Venkatesan (Janssen Pharmaceutica N. V.), U.S. 0,069,286, 2006; 14bJ. Liu, X. Deng, A. E. Fitzgerald, Z. S. Sales, H. Venkatesan, N. S. Mani, Org. Biomol. Chem. 2011, 9, 2654. 15M. Pippel, K. Boyce, H. Venkatesan, V. K. Phuong, W. Yan, T. D. Barrett, G. Lagaud, L. Li, M. F. Morton, C. Prendergast, X. Wu, N. P. Shankley, M. H. Rabinowitz, Bioorg. Med. Chem. Lett. 2009, 19, 6376. 16See C. E. Humphrey, M. Furegati, K. Laumen, L. La Vecchia, T. Leutert, J. C. D. Mueller-Hartwieg, M. Voegtle, Org. Process Res. Dev. 2007, 11, 1069, and references therein. 17M. T. Burger, D. Bussiere, J. Murray, S. Ng, Z.-J. Ni, K. B. Pfister, A. S. Wagman, Y. Zhou (Chiron Corporation), WO 001406, 2007. 18 18aK. C. Nicolaou, T. Ohshima, F. Murphy, S. Barluenga, J. Xu, N. Winssinger, Chem. Commun. 1999, 809; 18bK. C. Nicolaou, F. Murphy, S. Barluenga, T. Ohshima, H. Wei, J. Xu, D. L. F. Gray, O. Baudoin, J. Am. Chem. Soc. 2000, 122, 3830. 19 19aP. V. Chaturvedula, L. Chen, R. Civiello, A. P. Degnan, G. M. Dubowchik, X. Han, X. J. J. Jiang, J. E. Macor, G. S. Poindexter, G. O. Tora, G. Luo, US 0149503, 2007; 19bX. Han, R. L. Civiello, H. Fang, D. Wu, Q. Gao, P. V. Chaturvedula, J. E. Macor, G. M. Dubowchik, J. Org. Chem. 2008, 73, 8502. 20J. Y. Cha, G. L. Burnett, Y. Huang, J. B. Davidson, T. R. R. Pettus, J. Org. Chem. 2011, 76, 1361. 21T. Kuroita, T. Oda, Y. Asano, N. Taya, K. Iwanaga, H. Tokuhara, Y. Fukase (Takeda Pharmaceutical Company Limited), WO 139941, 2008. 22 22aJ. Surtees, V. Marmon, E. Differding, V. Zimmermann (Ucb Farchim S.A.), WO 064637, 2001; 22bC. Ates, J. Surtees, A.-C. Burteau, V. Marmon, E. Cavoy (UCB, S.A.), WO 014080, 2003; 22cB. M. Kenda, A. C. Matagne, P. E. Talaga, P. M. Pasau, E. Differding, B. I. Lallemand, A. M. Frycia, F. G. Moureau, H. V. Klitgaard, M. R. Gillard, B. Fuks, P. Michel, J. Med. Chem. 2004, 47, 530; 22dJ. Surtees, F. Lurquin, O. Diouf (Ucb, S.A.), WO 028435, 2005. 23N. Khiri, E. Bertrand, M.-J. Ondel-Eymin, Y. Rousselin, J. Bayardon, P. D. Harvey, S. Jugé, Organometallics 2010, 29, 3622. 24 24aD. Choi, J. P. Stables, H. Kohn, J. Med. Chem. 1996, 39, 1907; 24bS. V. Andurkar, J. P. Stables, H. Kohn, Tetrahedron: Asymmetry 1998, 9, 3841; 24cP. Morieux, J. P. Stables, H. Kohn, Bioorg. Med. Chem. 2008, 16, 8968. 25 25aA. Davies, M. Lamb, P. Lyne, P. Mohr, B. Wang, T. Wang, D. Yu (Astrazeneca), WO 082392, 2006; 25bJ. M. Gozgit, G. Bebernitz, P. Patil, M. Ye, J. Parmentier, J. Wu, N. Su, T. Wang, S. Ioannidis, A. Davies, D. Huszar, M. Zinda, J. Biol. Chem. 2008, 283, 32334. 26T. Wang, S. Ioannidis, L. Almeida, M. H. Block, A. M. Davies, M. L. Lamb, D. A. Scott, M. Su, H.-J. Zhang, M. Alimzhanov, G. Bebernitz, K. Bell, M. Zinda, Bioorg. Med. Chem. Lett. 2011, 21, 2958. 27The Rh-mediated asymmetric hydrogenation of substrate S13 usually leads to moderate results in terms of conversion and enantioselectivity. For literature precedents, see W. Zhang, X. Zhang, Angew. Chem. 2006, 118, 5641; Angew. Chem. Int. Ed. 2006, 45, 5515, and references therein. 28See G. B. Shinde, N. C. Niphade, S. P. Deshmukh, R. B. Toche, V. T. Mathad, Org. Process Res. Dev. 2011, 15, 455, and references cited therein for recent synthetic approaches towards cinacalcet. 29For selected examples of asymmetric total syntheses of rivastigmine, see, for example: 29aK. Han, C. Kim, J. Park, M.-J. Kim, J. Org. Chem. 2010, 75, 3105; 29bK. Arunkumar, M. Appi Reddy, T. Sravan Kumar, B. Vijaya Kumar, K. B. Chandrasekhar, P. Rajender Kumar, M. Pal, Beilstein J. Org. Chem. 2010, 6, 1174, and references therein. 30I. D. Gridnev, M. Yasutake, N. Higashi, T. Imamoto, J. Am. Chem. Soc. 2001, 123, 5268. 31P. J. Vankawala, N. Kolla, C. R. Elati, M. Sreenivasulu, K. A. Kumar, Y. Anjaneyulu, S. Venkatraman, A. Bhattacharya, V. T. Mathad, Synth. Commun. 2007, 37, 3439. 32 32aK. M. J. Brands, J. F. Payack, J. D. Rosen, T. D. Nelson, A. Candelario, M. A. Huffman, M. M. Zhao, J. Li, B. Craig, Z. J. Song, D. M. Tschaen, K. Hansen, P. N. Devine, P. J. Pye, K. Rossen, P. G. Dormer, R. A. Reamer, C. J. Welch, D. J. Mathre, N. N. Tsou, J. M. McNamara, P. J. Reider, J. Am. Chem. Soc. 2003, 125, 2129; 32bK. M. J. Brands, S. W. Krska, T. Rosner, K. M. Conrad, E. G. Corley, M. Kaba, R. D. Larsen, R. A. Reamer, Y. Sun, F.-R. Tsay, Org. Process Res. Dev. 2006, 10, 109. 33 33aT. Matsuda, K. Tsuji, T. Kamitanaka, T. Harada, K. Nakamura, T. Ikariya, Chem. Lett. 2005, 34, 1102; 33bK. Bogár, J.-E. Bäckvall, Tetrahedron Lett. 2007, 48, 5471. Citing Literature Volume17, Issue50December 9, 2011Pages 13978-13982 ReferencesRelatedInformation